In the context of colorectal carcinoma, CDK5 represents an attractive target for treatment due to its high expression in tumor tissue, involvement in various aspects of oncogenesis, and potential to enhance the effects of DNA-damaging agents [9,13,14,24]. This evidence concerns the gene CDK5 and neoplasm.